Menu
Washingtoner
  • Home
  • Business
  • Technology
  • Arts
  • Construction
  • Real Estate
  • Software
  • Transportation
  • Health
Washingtoner

FDA Clears SeptiCyte® RAPID - The First One-Hour, Direct-from-Blood Sepsis Test
Washingtoner/10142320

Trending...
  • City of Spokane Responds to SREC Board's Move to Terminate Spokane Fire Department Contract
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
  • Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
Superior Sepsis Diagnostic Performance of SeptiCyte® RAPID... Immunexpress to Present SeptiCyte® RAPID Comparative Data Against ...
SEATTLE and BRISBANE, Australia, Nov. 30, 2021 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The cleared test is an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalized patients suspected of sepsis.

Immunexpress has been a leader in host response sepsis diagnostics, and this second FDA clearance translates its biomarker technology to the sample-to-answer Biocartis Idylla™ near-patient testing platform. SeptiCyte® RAPID contains all the reagents needed for quantification of gene expression using a reverse transcription polymerase chain reaction (PCR) to determine the relative expression levels of host response genes directly from whole blood. The process is fully automated in a user-friendly, hands-free format, and a result is obtained in one hour.

"SeptiCyte® RAPID has the potential to transform sepsis diagnosis, addressing a critically unmet need in the ICU," said Roy Davis, M.D., Ph.D., Chief Medical Officer of Immunexpress. "SeptiCyte® RAPID has been evaluated in hospitals since 2019. Major hospital systems with which we have worked are anxiously waiting to incorporate this into the current diagnostic tool set, allowing clinicians to make swift and accurate clinical decisions, ultimately improving patient outcomes."

Rollie Carlson, Ph.D., Chief Executive Officer of Immunexpress, commented, "It has been a long journey to transfer our clinically proven novel biomarker technology from our 8 hour FDA-cleared SeptiCyte® LAB product in 2017, to the advanced 1 hour sample-to-answer Biocartis Idylla™ testing platform. This FDA clearance could not have been achieved without the dedication of the Immunexpress team, the support of our investors, and our clinical partners around the globe."

The increasing incidence of sepsis, which has accelerated with the COVID 19 pandemic, is well recognized and has been generally attributed to the growing prevalence of chronic conditions in aging populations. The clinical presentation of sepsis is often hard to identify early; fever is not always present, and it can often go unrecognized clinically for extended periods. Sepsis remains a leading cause of morbidity and mortality among intensive care unit (ICU) patients. For each hour that treatment initiation is delayed after diagnosis, sepsis-related mortality increases by approximately 8%[1]. Therefore, maximizing effective care requires early recognition and initiation of treatment protocols. SeptiCyte® RAPID will be the first FDA cleared test to differentiate sepsis from non-infectious systemic inflammation to aid in a sepsis diagnosis within approximately one hour for patients suspected of sepsis.

More on Washingtoner
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • Spokane City Council Adopts Engagement and Enforcement Ordinances
  • Spokane City Council Approves Safe and Welcome in Spokane Ordinance
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments

FDA clearance was based on data from retrospective and prospective studies validating the clinical accuracy of SeptiCyte® RAPID. The retrospective clinical study included 8 sites in the United States and Europe from the MARS clinical trial (NCT01905033) and VENUS clinical trial (NCT02127502). The prospective study, NEar PatienT MolecUlar TestiNg in SEpsis (NEPTUNE), evaluated real-time performance of SeptiCyte® RAPID in a clinical setting at Emory University, Rush University and the University of Southern California. In both retrospective and prospective studies, the sepsis status of patients was determined by a three-member panel of expert physicians.  The data reinforces the utility of quickly testing the patient's immune host response to determine if there is an underlying sepsis infection. Immunexpress will immediately commercialize SeptiCyte® RAPID to ensure broad availability across the United States in 2022.

About SeptiCyte® RAPID
SeptiCyte® RAPID is a gene expression assay using reverse transcription polymerase chain reaction (PCR) to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene® Blood RNA Tube. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis. SeptiCyte® RAPID generates a score (SeptiScore™) that falls within discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. SeptiCyte® RAPID is intended for in-vitro diagnostic use and is used on the Biocartis Idylla™ System.

SeptiCyte® RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). As of November 2021, SeptiCyte® RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis.

About Immunexpress
Immunexpress is a molecular diagnostic company, based out of Seattle, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's dysregulated immune response by quantifying and analyzing gene expression from whole blood, providing actionable results in about an hour to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID is a lab test for sepsis that combines SeptiCyte® technology with the Biocartis' Idylla™ platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis; diagnosing bacterial sepsis, viral sepsis, or fungal infections. This powerful combination of technologies enhances certainty for early sepsis diagnosis, to improve clinical outcomes and lower healthcare costs.

More on Washingtoner
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings

In March 2020, Immunexpress received CE Marking of SeptiCyte® RAPID and announced a commercialization partnership with Biocartis in Europe. In November 2021, Immunexpress received FDA clearance for SeptiCyte® RAPID.

For more information, visit http://www.immunexpress.com/. Follow Immunexpress on Twitter and LinkedIn.

About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs, with a focus in oncology, which represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

*Immunexpress is licensed to use the Idylla™ trademark from Biocartis NV.

Media Contacts:
Maggie Beller
Russo Partners, LLC
(646) 942-5631
[email protected]






1 Kumar A et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine. 2006;(34):1589-1596.


SOURCE Immunexpress, Inc.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
  • Spokane: Pedestrian and Bike Improvement Projects Begin Next Week
  • Spokane: Flags Lowered for Former Secretary of State Ralph Munro
  • Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
  • Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI)
  • Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits
  • Discover the Beauty of the USA with AmericaTheBeautifulDay.net!
  • databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • City of Spokane Responds to SREC Board's Move to Terminate Spokane Fire Department Contract
  • Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
  • Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
  • Suzanne Harp named Managing Director in Texas, USA
  • $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
  • Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
  • This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
_catLbl0 _catLbl1

Popular on Washingtoner

  • Custom Android TV Box & OTT TV Box Solutions with PCBA and Mold Design Expertise - 173
  • Pregis Empowers Foam-in-Place Customers to Fight Water Insecurity with Inspyre Film - 167
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 166
  • Advanced Solar Space Technology; Record Efficiency of 15.7%; Agreement to Provide NOVI Space with Rollable PV Array Blankets for Space Launch in 2026 - 152
  • DealMagik Successfully Concludes National Floral Design Contest with Over 150 Submissions - 143
  • ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team - 125
  • Shelter Structures America Appoints Shannon Heller as New Inventory Manager, Bolstering Operational Excellence in the Commercial Tent Industry - 123
  • Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case - 111
  • $77.8 Million in Revenue Through April 2025, Confirms Full-Year Guidance; Fast-Track to 400 Million Run Rate; $1 Billion Target After Key Acquisition - 109
  • SheepFeast Launches "1 Million Discipled" Global Initiative to Empower Disciple-Making Around the World - 106

Similar on Washingtoner

  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • Winners Announced for Asia Pacific Business Awards 2024-2025
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute